Pre-close trading update confirms 2019 trading in-line with expectations
Meet our inhalation experts at Drug Delivery to the Lungs (DDL) 2019
VR315US: Hikma submits response to FDA
Vectura to present latest science at Drug Delivery to the Lungs (DDL) 2019
Vectura Group appoints New Chief Executive Officer
Results of the General Meeting held on 10th October 2019
Vectura provides update on GSK litigation
Vectura delivers strong H1 2019 financial performance
Proposed increased capital return to shareholders of approx. £60m
Proposed £50 million capital return and trading update
Vectura Group Plc announces leadership changes
QVM149 submission means early $2.5m payment for Vectura
Vectura data to be shared at ATS 2019
Vectura wins US GSK patent litigation and awarded $89.7m in damages by jury
R&D: Transformation frees up more resources for innovation
Our transformed ways of working have created capacity for new, innovative programmes.
Vectura reports strong 2018 financial and operational performance
Vectura Group plc today announces its preliminary results for the year ended 31 December 2018.
Pre-close trading update confirms good progress against 2018 goals
The Group expects revenue to be in line with, and EBITDA to be materially above, current market consensus expectations.
Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio
Vectura announces signing an agreement with Hikma Pharmaceuticals for the global development and commercialisation of generic versions of GSK’s Ellipta® portfolio.
Rising to the challenge of developing inhaled generic medicines
And why Vectura is well placed to innovate in this space.
Vectura Group Interim Results for H1 2018
Details of Vectura Group's interim results for the six months ended 30 June 2018.
Fundraising for AsthmaUK
Vectura deploys its international pedal power for charity.
Bringing nebuliser device and formulation together
Our unique capabilities mean "all the pieces of the jigsaw fit".
New product creation – from paper to market
We take products from a blank piece of paper right the way through to market, but the patient is always at the centre of what we do.
A large and untapped US market with few new entrants into this complex space.
Breelib™ meets iloprost
A modern nebuliser for an established drug.